Alpha Centric Advisors LLC Mersana Therapeutics, Inc. Transaction History

Alpha Centric Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 25, 2022	SELL	$5.48 - $9.86 $358,940 - $645,830	-65,500 Closed	0 $0
Q3 2021 Mar 09, 2022	BUY	$8.56 - $14.47 $171,200 - $289,400	20,000 Added 43.96%	65,500 $618,000
Q2 2021 Mar 09, 2022	BUY	$13.28 - $18.07 $199,200 - $271,050	15,000 Added 49.18%	45,500 $618,000
Q1 2021 Mar 09, 2022	BUY	$15.31 - $26.52 $396,529 - $686,868	25,900 Added 563.04%	30,500 $493,000
Q4 2020 Mar 11, 2022	BUY	$16.84 - $27.59 $29,470 - $48,282	1,750 Added 61.4%	4,600 $122,000
Q3 2020 Mar 11, 2022	BUY	$16.2 - $25.7 $46,170 - $73,245	2,850 New	2,850 $53,000

93.6M

34.3K

14K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $914M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.